DHODH Inhibition Represents a Therapeutic Strategy and Improves Abiraterone Treatment in Castration-Resistant Prostate Cancer

The authors showed that dihydroorotate dehydrogenase (DHODH), an enzyme crucial in the pyrimidine biosynthesis pathway, was a promising therapeutic target for CRPC. The transcript levels of DHODH were significantly elevated in prostate tumors.